SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
GAITHERSBURG, Md., Feb. 20, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
| Date: | Monday, February 27, 2017 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
